摘要
Major depressive disorder(MDD)is a disabling and highly prevalent mood disorder as well as a common cause of suicide.Chronic stress,inflammation,and intestinal dysbiosis have all been shown to play crucial roles in the pathophysiology of MDD.Although conventional antidepressants are widely used in the clinic,they can take weeks to months to produce therapeutic effects.The discovery that ketamine promotes fast and sustaining antidepressant responses is one of the most important breakthroughs in the pharmacotherapy of MDD.However,the adverse psychomimetic/dissociative and neurotoxic effects of ketamine discourage its chronic use.Therefore,agmatine,an endogenous glutamatergic modulator,has been postulated to elicit fast behavioral and synaptogenic effects by stimulating the mechanistic target of rapamycin complex 1 signaling pathway,similar to ketamine.However,recent evidence has demonstrated that the modulation of the NLR family pyrin domain containing 3 inflammasome and gut microbiota,which have been shown to play a crucial role in the pathophysiology of MDD,may also participate in the antidepressant-like effects of both ketamine and agmatine.This review seeks to provide evidence about the mechanisms that may underlie the fast antidepressant-like responses of agmatine in preclinical studies.Considering the anti-inflammatory properties of agmatine,it may also be further investigated as a useful compound for the management of MDD associated with a pro-inflammatory state.Moreover,the fast antidepressant-like response of agmatine noted in animal models should be investigated in clinical studies.
基金
Supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico,No.310113/2017-2
the CNPq Research Productivity Fellowship.
